Data from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7451572
M
Michelle Kuhne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
74
Papers
2.8K
Citations
16
h-index
19
i10-index
Michelle Kuhne is an academic researcher from Gilead Sciences (United States). The author has contributed to research in topics: Immunotherapy and Immune Responses & Monoclonal and Polyclonal Antibodies Research & Protein Tyrosine Phosphatases. The author has an h-index of 16, co-authored 63 publications.
ORCID: 0009-0007-4987-7654Papers by this author
worksData from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7451572.v1
Supplementary Figure S3 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27034465
Supplementary Figure S2 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27034468.v1
Supplementary Table S1 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27034459.v1
Supplementary Figure S1 from Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27034471.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat